Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an announcement.
ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in the Phase I clinical trial of their new generation fusion protein, IMC-003/IMM72. This milestone is significant for the company’s clinical research efforts and sets the stage for future trials, highlighting their commitment to advancing innovative treatments in the biopharmaceutical industry.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies. The company specializes in genetic engineering modifications to create advanced fusion proteins, with a strong emphasis on owning global intellectual property rights for its products.
Average Trading Volume: 4,742,224
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.28B
For an in-depth examination of 1541 stock, go to TipRanks’ Overview page.